treprostinil / Generic mfg. - LARVOL DELTA

Treprostinil, a Prostacyclin Analog, Mitigates Profibrotic Signaling in Scleroderma Fibroblasts via the EP2–PPARG–SMARCA4 Pathway (SSWC 2026) - No abstract available

Immunology • Scleroderma • Systemic Sclerosis • PPARG • SMARCA4

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects. (PubMed, Biomolecules) - "Although vasodilators targeting the endothelin, nitric oxide, and prostacyclin pathways remain the therapeutic backbone, newer agents-including the activin signal inhibitor sotatercept and inhaled treprostinil-have expanded treatment options. Immune-targeted therapies such as glucocorticoids, cyclophosphamide, mycophenolate mofetil, rituximab, and IL-6 receptor inhibitors may benefit inflammation-dominant PAH phenotypes, while fibrotic phenotypes continue to demonstrate limited responsiveness...Despite these developments, substantial unmet needs remain, including the absence of disease-specific therapeutic strategies, limited biomarker integration into clinical practice, and a scarcity of large, well-designed trials targeting individual CTD subtypes. Addressing these gaps will be essential for improving prognosis in patients with CTD-PAH."

Journal • Review • Cardiovascular • Fibrosis • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • IL6 • NPPB

Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy. (PubMed, Adv Ther) - P3 | "Oral treprostinil is a safe and efficacious treatment option and has been shown to further improve clinical parameters and risk status in patients with PAH on background dual therapy."

Journal • Monotherapy • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Case Report: Immune checkpoint inhibitor-associated pulmonary hypertension. (PubMed, Front Cardiovasc Med) - "We report a case of a 65-year-old male who developed severe pulmonary arterial hypertension (PAH) following treatment with the programmed cell death protein 1 inhibitor tislelizumab. Following the initiation of a triple combination targeted therapy for PAH comprising macitentan, riociguat, and treprostinil, the patient's condition improved significantly...To date, no specific diagnostic or treatment guidelines exist for this condition due to its rarity. Therefore, there is an urgent need for more case reports, shared experiences, and clinical research to assist clinicians in identifying optimal strategies for the diagnosis and management of this complication."

Checkpoint inhibition • Journal • Cardiovascular • Gastrointestinal Disorder • Hypertension • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

PH in Interstitial Lung Disease: Twist in the Fibrotic Tale (ISHLT 2026) - "It will review the latest evidence, including findings from the INCREASE trial on inhaled Treprostinil, and discuss treatment thresholds with special attention to the management of "borderline PH" in this patient population. Attendees will gain a comprehensive understanding of current diagnostic and therapeutic strategies to optimize care for this complex group."

Cardiovascular • Fibrosis • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Inhaled Treprostinil Use and Pre-Transplant Outcomes in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Pre-transplantation • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

Artisan Interim Analysis: Early and High-Dose Treprostinil Reduces mPAP and Improves Right Heart Function in PAH (ISHLT 2026) - "Abstract is embargoed at this time."

Cardiovascular

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Pulmovant, Inc.

New P2 trial • Cardiovascular • Hypertension • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

EARLY AND HIGH-DOSE TREPROSTINIL THERAPY TARGETING PRESSURE TO IMPROVE RIGHT VENTRICULAR FUNCTION IN PULMONARY ARTERIAL HYPERTENSION: ARTISAN INTERIM ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension. (PubMed, Adv Ther) - "Parenteral PCA therapy is recommended for patients at intermediate-high and high risk, and early initiation-particularly in combination regimens-is associated with improved survival in real-world and post hoc analyses.The 2002 approval of the parenteral PCA treprostinil (Remodulin®) marked a significant advancement in PCA therapy...The article also provides perspectives and practical guidance from experienced practitioners on the initiation and maintenance of SC PCA therapy, emphasizing how improvements in pump technology can help overcome barriers to use. Addressing these challenges through improved design, education, and support may help bridge the gap between evidence-based recommendations and real-world practice.Graphical abstract available for this article."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Rapid Inpatient Uptitration of Inhaled Treprostinil in PH-ILD Patients with Severe Phenotype. (PubMed, Adv Respir Med) - "No readmissions occurred within 90 days. This study demonstrates that rapid inpatient uptitration of iTre in severe PH-ILD is feasible and well-tolerated, with preliminary evidence of short-term hemodynamic improvement."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease. (PubMed, Pulm Circ) - "Patients with baseline pulmonary arterial wedge pressure (PAWP) < 12 mmHg had better outcomes. Open-label scTRE was associated with a spectrum of clinically relevant benefits in a select group of LHD-PH and CLD-PH patients recently hospitalized for RV failure and was well tolerated."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension. (PubMed, Pediatr Pulmonol) - "Our study shows a potential benefit of treprostinil use in moderate-to-severe BPD-PH; larger studies are needed to validate our findings and guide decision-making around treprostinil initiation and duration."

Journal • Retrospective data • Bronchopulmonary Dysplasia • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study. (PubMed, Medicine (Baltimore)) - "In neonates with PPHN unresponsive to iNO, intravenous treprostinil was associated with faster improvement in oxygenation and earlier iNO tapering among non-responders, despite greater baseline severity. Classifying early treatment responses could assist in selecting infants who are more likely to benefit from additional therapies."

Journal • Observational data • Retrospective data • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Inhaled Treprostinil: Improvements in Hemodynamics and Quality of Life for Patients with Pulmonary Arterial Hypertension on Dual or Triple Therapy. (PubMed, J Clin Med) - "QoL improved, with KCCQ-12 overall and clinical summary scores increasing from 59.1 ± 27.4 to 67.1 ± 26.5 and 78.1 ± 26.3 to 87.5 ± 21.2, respectively. Treprostinil inhalation improved hemodynamics and patient-reported outcomes despite prior combination improved hemodynamics and tended to enhance QoL in patients with PAH receiving combination vasodilator therapy."

HEOR • Journal • Cardiomyopathy • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Reduction in Prostacyclin Infusion Errors Following a Comprehensive Multidisciplinary Process Transformation for Hospitalized Pediatric Patients with Pulmonary Hypertension: A Quality Improvement Project. (PubMed, J Pediatr Pharmacol Ther) - "Our multidisciplinary comprehensive CPI decreased errors associated with prostacyclin infusions on the MedFusion pump, and continuous efforts have maintained low error rates."

Journal • Cardiovascular • Hypertension • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease. (PubMed, Respir Investig) - "Considering its long-term clinical benefits and tolerability, inhaled treprostinil is a promising treatment option for patients with PH-ILD."

Journal • Cardiovascular • Cough • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

Clinical Experience with Treprostinil to Selexipag Transition in Pediatric Pulmonary Hypertension (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain. (PubMed, Br J Anaesth) - "We show that prostaglandin agonists can produce a surprising analgesic effect. Prostaglandin receptor agonists show promise in preventing and resolving CPSP by upregulating S100A8/A9 through the PKA-STAT3 pathway in innate immune cells, suggesting a new therapeutic approach for chronic postsurgical pain."

Journal • Preclinical • Pain • S100A8

Protective effects of treprostinil and ischemic preconditioning on hepatic ischemia-reperfusion injury and biomarkers in experimental studies in rats. (PubMed, World J Gastrointest Surg) - "HIRI results in oxidative stress and cytokine overexpression, which deteriorate hepatic function and accelerates myocardial damage. Treprostinil and IP are promising strategies for preventing reperfusion-induced cellular and systemic damage."

Journal • Preclinical • Cardiovascular • Hepatology • Liver Failure • Oncology • Reperfusion Injury • Transplantation • EDN1 • IL1B • TNFA

Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018-2024). (PubMed, Front Pain Res (Lausanne)) - "The drugs with the highest headache risk based on ROR included glecaprevir/pibrentasvir (ROR = 10.445), sofosbuvir/velpatasvir (ROR = 9.729), and eptinezumab-jjmr (ROR = 6.775). Top frequently reported drugs were apremilast, treprostinil, and adalimumab...Early-onset headaches (≤7days) were particularly associated with ofatumumab and fingolimod. Late-onset headaches (>90days) were linked to treprostinil and infliximab-dyyb. This large-scale pharmacovigilance study identifies multiple drugs and therapeutic classes with significant associations to headache as an ADR. These findings highlight the need for proactive headache monitoring, particularly during early treatment phases, and warrant further prospective investigations to understand mechanisms and preventive strategies."

Adverse events • Journal • Pain

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases. (PubMed, JA Clin Rep) - No abstract available

Journal • Cardiovascular • Hypertension • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A 'call to action' in determining and estimating a minimum important difference (MID) in 6-minute walking distance (6MWD) in PH-ILD (BTS WM 2025) - P2/3 | "The trial comprises of both a treatment (Treprostinil, TRT) and placebo (PLB) arm...The SEE methodology provided a MCID of 31 m however, when an expert response was excluded based on task comprehension concerns and lack of PH experience, an MCID of 28.6 m was established. Conclusion This study has established an interim 6MWD MID for PH-ILD that ranges between 19 m to 31 m. Due to the variability of the MID for PH-ILD, this study is a 'call-to-action' for more research to be conducted."

Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Defining the antifibrotic mechanisms of treprostinil in pulmonary fibrosis (BTS WM 2025) - "Fibroblast proliferation was also inhibited in a concentration-dependent manner by Treprostinil and there were additive effects when combined with nintedanib, pirfenidone, or nerandomilast. Antifibrotic effects of Treprostinil were detected in IPF derived PCLS. Further studies are ongoing to establish the underlying mechanism as there were additive effects of Treprostinil with established antifibrotic agents which may have important clinical implications."

Cardiovascular • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • RHOA • SERPINE1 • TGFB1

The differential effects of cAMP mobilizing agents on TGF-β-induced extracellular matrix in human lung-derived fibroblasts: insights into therapeutic targets for lung fibrosis. (PubMed, Respir Res) - "The anti-fibrotic properties of treprostinil are primarily mediated by the IP receptor, acting through both Gαs-dependent and -independent pathways. Understanding the differential effects of cAMP-mobilizing pathways on HLF fibrotic signatures can provide insight into developing novel targets to manage IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • TGFB1